- About
- PsychU For You
- Topics
- Events
- Content
Test VLE
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Test VLE
This review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) with a focus on those who are living with this condition or who are caring for those who live with this condition in the Long-Term Care (LTC) setting. This information is intended to help provide a better understanding of the implications of this disorder that are associated with it in the LTC environment including prevalence, medication use, costs of care and the challenges associated with antipsychotic use. It also describes the diagnostic criteria for AAD and explores the potential pathobiological correlations in AAD. Objectives:
- Learn about agitation associated with Alzheimer’s Dementia (AAD) as a highly prevalent disorder that is present in all stages and severities for those with Alzheimer’s dementia
- Gain understanding about the potential pathobiological elements, and the associated neurotransmitters implicated with AAD
- Review information related to patient and care-giver burden as well as the healthcare utilization and costs associated with AAD
- Consider the class of antipsychotics and the challenges associated with using this class of medications in the Long-Term Care setting
Amie Blaszczyk, Pharm.D., BCGP, BCPS, FASCP
Long Term Care Medical Science Liaison
Amie Blaszczyk, Pharm.D., BCGP, BCPS, FASCP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Registration
- PsychU For You
